RXi Pharmaceuticals (NasdaqCM: RXII)

Biotechnology

Get your copy of the RXi Fact Sheet: Here

Get your copy of the RXi Power Point: Here

Value Proposition

• Over the last five years, “Big Pharma” has invested $1.6 billion acquiring companies with RNAi technology.
  • Merck bought Sirna for $1.1 billion for its RNAi technology.
  • Roche paid Alnylam $300 million to acquire access to its RNAi technology.
• The near-term opportunity for investors revolves around RXi obtaining a partnering agreement with “Big Pharma”.
  • RXi can potentially earn $1 million to $5 million from each gene that it creates for “Big Pharma”.
  • “Big Pharma” will take the gene and develop the drug and incur the expense of clinical trials.
• RXi believes it will secure a licensing agreement in the near future. When RXi secures one licensing agreement with “Big Pharma”, it should lead to other licensing agreements and to substantial revenue and ultimately the possibility of a buy-out.

News Highlight

RXi Pharmaceuticals lead small-cap percentage gainers: read more.

Investment Highlights

• Founded by a Nobel Prize Winner, RXi has the best RNAi team in the world (see bios).
• RXi has its own delivery system for its RNAi which is a major competitive advantage.
• RXi solves a major challenge for “Big Pharma” with its proprietary self-delivery system.
• RXi’s RNAi technologies address multi-billion therapeutic markets.
• RXi was banked by Fidelity at $8.12 a share in May 2008 for $8.7 million.

Company Overview

RXi Pharmaceuticals was founded by Nobel Prize Winner, Dr. Craig Mello who received the Nobel Prize in Medicine for his groundbreaking work in the co-discovery of RNAi (RNA interference). RNAi compounds are a new class of drugs that block or “turn off” defective genes. RNAi technology allows RXi the ablility to make drug candidates for any gene within three-to-six-months. RXi’s proprietary delivery system is built into the RNAi compound which migrates into the cell to turn off the defective gene. In essence, RXi is a drug factory for major pharmaceutical companies (“Big Pharma”).

Recent News

Recent News: RXi Pharmaceuticals Corp. 05/11/10 8:30 AM EDT RXi Pharmaceuticals CEO to Present at the Rodman & Renshaw Annual Global Healthcare Conference - Business Wire 05/04/10 8:30 AM EDT RXi Demonstrates Robust in vivo Uptake and Significant Silencing Using its Self-Delivering rxRNA(TM) Compounds Administered to Mouse Retinal Cells - Business Wire 04/23/10 8:30 AM EDT RXi Pharmaceuticals to Deliver Presentations at Upcoming Conferences Outlining the Development and Progression of its Next Generation rxRNA(TM) Therapeutic Platform - Business Wire 04/19/10 7:00 AM EDT RXi Pharmaceuticals Presents at AACR Conference, Highlighting the Potential for RNAi Therapeutics in Oncology - Business Wire 04/12/10 8:35 AM EDT RXi Pharmaceuticals and miRagen Therapeutics Announce Formation of Research Collaboration in the Field of microRNA - Business Wire 04/12/10 8:30 AM EDT RXi Pharmaceuticals Announces Formation of microRNA Research Collaboration with Mirna Therapeutics - Business Wire

May 15 10:33 AM EDT